Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Trilucent breast implants

This article was originally published in The Gray Sheet

Executive Summary

Product liability suit filed Aug. 10 in California federal court related to development, manufacture or sale of the "potentially dangerous" soy-based breast implants names Inamed, AEI (formerly Collagen Aesthetics), Cohesion Technologies, TUV, LipoMatrix, and Washington University, St. Louis as defendants. Filed by Miami attorney Jeffrey Herman of the law firm Herman & Mermelstein, the suit follows a June advisory issued by Britain's Medical Devices Agency after reports of rupture and toxicity were linked to the implants (1"The Gray Sheet" June 12, p. 12). Roughly 9,000 procedures were performed in Europe between 1995-1999; about 2,000 woman have had their implants removed

Latest Headlines
See All
UsernamePublicRestriction

Register

MT013739

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel